This year's For­tune 500 list is out. And phar­ma com­pa­nies saw ma­jor prof­it growth

2021 was a year of good for­tune for phar­ma­ceu­ti­cal com­pa­nies — at least the ones on this year’s For­tune 500 list. Many saw a mas­sive surge in prof­its last year, led by Gilead and its mam­moth 4,961% growth.

How­ev­er, it ap­pears Gilead isn’t alone in that re­spect. De­spite its gains, the com­pa­ny ac­tu­al­ly fell 13 spots in For­tune’s rank to No. 129, as sev­er­al oth­er com­pa­nies more than dou­bled their prof­its.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.